Behavior
Conduct extensive pain, sensory, motor, and cognitive behavioral testing.
MD Biosciences offers well-characterized neurodegeneration models to advance research in diseases such as multiple sclerosis, Parkinson's disease, and stroke/ischemia. Our state-of-the-art facilities and expert team deliver a multifaceted approach with clinically relevant assessments, including histology, immunohistochemistry (IHC), biomarker analysis, behavioral assessments, and in vivo electrophysiology. Explore our comprehensive models and assessments designed to deepen understanding of neurological diseases and drive the development of effective therapies.
Clinical symptoms are recorded on a 0-5 scale during daily examinations of each animal for signs of neurological symptoms or paralysis. The figure shows that clinical evidence of disease typically appears around day 10 and peaks by day 16.
The figure shows the behavior of 4VO rats, where test-treated rats located the platform similarly to sham rats, while vehicle-treated rats were unable to do so.
The figure shows motor evoked potentials in naïve, mild, and severe EAE models. Electrophysiological characterization shows how early EAE causes desynchronized neural activity and hypersensitivity, leading to motor and sensory loss in later stages.
MD Biosciences offers comprehensive in vivo measures and endpoint assessments, delivering robust data packages to support critical research decisions in the evolving landscape of drug development and biomedical research.
Conduct extensive pain, sensory, motor, and cognitive behavioral testing.
Explore inflammatory and pain biomarkers in disease-specific tissues.
Characterize tissue and cellular changes in disease, pain, and neurodegeneration.
Measure motor and sensory evoked potentials to assess disease progression and pain.